Rani Therapeutics Reports Q2 Update; RT-114 Expansion Data Expected By Year-End

Rani Therapeutics reported Q2 2026 results showing a narrower net loss, alongside new contract revenue and continued progress in its oral biologics pipeline. The combination of reduced downside (smaller net loss) and incremental commercial momentum suggests an improving operating trajectory, though the update remains incremental due to lack of detailed figures. Overall, the news reads supportive for the company’s fundamentals rather than a major re-rating event.